The immunotherapy of Alzheimer's disease

Immunity and Ageing

Volumn 1, Issue , 2004, Pages

  Weksler, Marc E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA TOXOID; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SMALLPOX VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; BRAIN DISEASE; BRAIN FUNCTION; BRAIN HEMORRHAGE; CELLULAR IMMUNITY; CLEARANCE; CLINICAL OBSERVATION; CLINICAL TRIAL; COGNITION; DIPHTHERIA; DISEASE CONTROL; DNA LIBRARY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; ENCEPHALITIS; HUMAN; IMMUNOTHERAPY; LUNG EMBOLISM; MENINGOENCEPHALITIS; MENTAL DETERIORATION; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN INDUCTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SENILE PLAQUE; SERUM SICKNESS; SMALLPOX;

EID: 33747163419     PISSN: 17424933     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4933-1-2     Document Type: Review

References (47)

1. Grady D: Minimal Benefit is seen in drugs for Alzheimer's disease. New York Times:1. April 7, 2004
2. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 19:353-356.
3. Citron M: Beta-secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Trends Pharmacol Sci 2004, 25:92-97.
4. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F: A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004, 113:1456-1464.
5. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA: The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 2003, 23:5531-5535.
6. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
7. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
8. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash: GWA beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
9. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
10. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH: Intravenous Immunoglobulins containing Antibodies against b-amyloid for the Treatment of Alzheimer's Disease. Journal Neurol Neurosurg Psychiatry 2004, 75:1472-4.
11. Thucydides: The Peloponnesian War. Modern Library, New York; 1934:112.
12. Rhazes A: Treatise on the Small-Pox and Measles. New Syndenham Society, London:130.
13. Leung AKC: "Variolation" and vaccination in late imperial China, ca 1570-1911 in Vaccinia, Vaccination, Vaccinology Elsevier Paris 1996:65.
14. Timoni E: An account, or history, of the procuring of the smallpox by incision on inoculation, as it has for some time been practiced at Constantinople. Volume 29. Phil Trans R Soc London; 1714:72-82.
15. Baxby D: Edward Jenner's role in the introduction of smallpox vaccine in Vaccinia, Vaccination, Vaccinology Elsevier Paris 1996:59.
16. Jenner E: An inquiry into the causes and effects of the Variolae Vaccine, a disease discovered in some of the western counties of England particularly Gloucestershire, and known by the name of the cow pox. London, Sampson Low; 1798.
17. Plotkin SA, Fantini B, (Editors): Vaccinia, Vaccination, Vaccinology Elsevier Paris 1996.
18. Relyveld EH: A history of toxoids. in Vaccinia, Vaccination, Vaccinology Elsevier Paris 1996:95.
19. Behring EA: von & Kitasato, S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Theiren. Deutsche Med Wochenschr 1890, 16:1113-1114.
20. Brekke OH, Loset GA: New technologies in therapeutic antibody development. Curr Opin Pharm 2003, 3:544-550.
21. Gura T: Therapeutic antibodies: Magic bullets hit the target. Nature 2002, 417:584-586.
22. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
23. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG: A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
24. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
25. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
26. Sigurdsson EM, Wisniewski T, Frangione B: A safer vaccine for Alzheimer's disease? Neurobiol Aging 2002, 23:1001-1008.
27. Weksler ME, Goodhardt M, Szabo P: The effect of age on B cell development and humoral immunity. Springer Semin Immunopathol 2002, 24:35-52.
28. Pifer J, Hennes JL, Lee JM, Witte PL: Age-related differences in the immune response to immunization with human Abeta42 peptide. J Gerontol A Biol Sci Med Sci 2002, 57:B355-358.
29. Lee J-W, Jin F, Weksler ME: The Nature and Significance of Age-associated Autoimmunity. in The Molecular Pathology of Autoimmune Diseases 22002:1089.
30. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
31. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
32. Solomon B, Koppel R, Frankel D, Hanan-Aharon E: Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997, 94:4109-4112.
33. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98:8850-8855.
34. Brekke OH, Loset GA: New technologies in therapeutic antibody development. Curr Opin Pharm 2003, 3:544-550.
35. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
36. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P: Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002, 37(7):943-948.
37. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M: Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126:1935-1939.
38. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Abeta mmunotherapy. Science 2002, 298:1379.
39. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
40. Bregenholt S, Haurum J: Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther 2004, 4:387-396.
41. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003, 100:2023-2028.
42. DeMattos Ronald B, Boone Laura I, Hepburn Deena L, Maia Parsadanian, Bryan Matthew T, Ness Daniel K, Piroozi Kathy S, Holtzman David M, Bales Kelly R, Gitter Bruce D, Paul Steven M, Margaret Racke: Presentation Number:P4-358 Ninth International Conference on Alzheimer's Disease and Related Disorders. In Vitro and In Vivo Characterization of Beta-Amyloid Antibodies Binding to Cerebral Amyloid Angiopathy (CAA) and the Selective Exacerbation of CAA-Associated Microhemorrhage 2004.
43. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE: Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003, 23(24):8532-8538.
44. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
45. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004, 24:6144-6151.
46. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands. Proc Natl Acad Sci U S A 2003, 100:10417-10422.
47. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.